Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
Shionogi Co., Ltd announced it will invest USD 2.1 billion to increase its stake in ViiV Healthcare...
ViiV Healthcare
ViiV Healthcare’s Dovato Shows Non-Inferior Efficacy and Less Weight Gain in Pivotal PASO DOBLE Study
ViiV Healthcare, the HIV-focused subsidiary majority-owned by GSK with Pfizer and Shionogi as shareholders, has...
ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication
GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals...
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy
Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the...